FDFT1 and mevalonic aciduria: In support of our hypothesis, it has been reported that another squalene synthase inhibitor, zaragozic acid A, on skin fibroblasts from MK-deficient patients has shown increased residual MK enzyme activity, indicating that treatment of MKD with the supply of MDIs may prove beneficial in the prevention and treatment of the symptoms of MKD (Schneiders et al. 2006).